SCHEMBL1292018

SCHEMBL1292018

Cc1c(N2C(=O)CCC2[C@H](O)C(F)(F)F)ccc(C#N)c1C(F)(F)F

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1292016 1.00 AR (0.44) AR
SCHEMBL1292078 1.00 AR (0.44) AR
SCHEMBL15194003 1.00 AR (0.44) AR
SCHEMBL1292076 1.00 AR (0.44) AR
SCHEMBL1292127 1.00 AR (0.44) AR
SCHEMBL1291963 0.87 AR (0.53) AR
SCHEMBL1291964 0.87 AR (0.53) AR
SCHEMBL1291483 0.87 AR (0.53) AR
SCHEMBL1291479 0.87 AR (0.53) AR
SCHEMBL15194204 0.84 AR (0.43) AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9920044-B2 Selective androgen receptor modulators RADIUS PHARMACEUTICALS, INC. (US) 2018-03-20 US claimed
US-20150322059-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH, INC. 2015-11-12 US claimed
EP-2621901-B1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2015-07-29 EP claimed
US-20130217732-A1 Selective Androgen Receptor Modulators RADIUS HEALTH, INC. 2013-08-22 US claimed
EP-2621901-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS Radius Health, Inc (US) 2013-08-07 EP claimed
WO-2012047617-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH, INC. (US) 2012-04-12 WO claimed
US-9920044-B2 Selective androgen receptor modulators RADIUS PHARMACEUTICALS, INC. (US) 2018-03-20 US disclosed
US-20150322059-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH, INC. 2015-11-12 US disclosed
US-9133182-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2015-09-15 US disclosed
EP-2621901-B1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2015-07-29 EP disclosed
US-20130217732-A1 Selective Androgen Receptor Modulators RADIUS HEALTH, INC. 2013-08-22 US disclosed
EP-2621901-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS Radius Health, Inc (US) 2013-08-07 EP disclosed
WO-2012047617-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH, INC. (US) 2012-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322059-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS AR, SHBG, GPR119 AR 1/4885
US-20130217732-A1 Selective Androgen Receptor Modulators AR, SHBG, GPR119 AR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.